TrialBlood advances2026

Safety and efficacy of allogeneic CD19-directed CAR-T therapy CTX110 in relapsed/refractory B-cell non-Hodgkin lymphoma.

Joseph P McGuirk et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.